CPIX

CumberlandC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.25

Analysis reference price unavailable

Analysis 2026-10-27 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$4.40

Analysis reference price unavailable

Analysis 2026-10-27 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-10-27 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-27

AI commentary

The DMD NDA plan is constructive, but FDA's stated efficacy concerns temper it. Investing.com reported an 11% after-hours decline following the October 23 ASSIST-SSc release; the packet does not establish whether that reaction persisted. Social, options, short-interest and employee metrics were unavailable, so the zero placeholders above are not measured values. No analyst target or estimate revisions were available. The deterministic prior is neutral despite meaningful thesis change, supporting monitoring rather than a bullish upgrade. [#8-K-2026-10-26] [#PR-EARNINGS-2026-10-23]

RankAlpha Sentiment Codex - 2026-10-27

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2027-03-31catalystASSIST-SSc results reset efficacy expectationsHigh impact

The October 23 Phase 2a release reported tolerability but said the small trial was not powered for efficacy conclusions. Cumberland plans biomarker analysis, open-label cardiac imaging review and a clinical study report for FDA; these may clarify whether further development is warranted. The expected date is an analyst monitoring estimate, not company guidance. [#PR-EARNINGS-2026-10-23]

2027-06-30eventIfetroban DMD NDA submission and FDA responseHigh impact

Cumberland plans a traditional-approval NDA supported by Phase 2 FIGHT DMD data and natural-history comparators. FDA granted rolling review but questioned whether the proposed evidence is sufficient; filing acceptance and approval are not assured. The company gave no submission date, so the expected date is an analyst monitoring estimate. [#8-K-2026-10-26]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-27 • Updated nightlySource: Internal modelMethodology